Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CARMUSTINE Cause Malignant neoplasm progression? 90 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 90 reports of Malignant neoplasm progression have been filed in association with CARMUSTINE (carmustine). This represents 2.7% of all adverse event reports for CARMUSTINE.

90
Reports of Malignant neoplasm progression with CARMUSTINE
2.7%
of all CARMUSTINE reports
42
Deaths
56
Hospitalizations

How Dangerous Is Malignant neoplasm progression From CARMUSTINE?

Of the 90 reports, 42 (46.7%) resulted in death, 56 (62.2%) required hospitalization, and 2 (2.2%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CARMUSTINE. However, 90 reports have been filed with the FAERS database.

What Other Side Effects Does CARMUSTINE Cause?

Off label use (454) Febrile neutropenia (297) Myelodysplastic syndrome (295) Disease progression (241) Acute myeloid leukaemia (180) Thrombocytopenia (174) Pyrexia (152) Drug ineffective (149) Mucosal inflammation (148) Second primary malignancy (141)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which CARMUSTINE Alternatives Have Lower Malignant neoplasm progression Risk?

CARMUSTINE vs CARTEOLOL CARMUSTINE vs CARVEDILOL CARMUSTINE vs CASIMERSEN CARMUSTINE vs CASIRIVIMAB CARMUSTINE vs CASIRIVIMAB\IMDEVIMAB

Related Pages

CARMUSTINE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression CARMUSTINE Demographics